H3-DYNAMICS
23.11.2022 07:01:43 CET | Business Wire | Press release
The future of hydrogen aviation powered by H3 Dynamics’ distributed hydrogen propulsion nacelles has taken flight for the very first time in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121006001/en/
H3 Dynamics distributed hydrogen electric nacelles proven on first flight (Photo: Business Wire)
Following the announcement of its hydrogen aviation concept back in 2018, H3 Dynamics managed to become a topic at an Oval Office press conference on the very next day, and started what is now a global hydrogen aviation movement.
In November 2021, H3 Dynamics completed its first working hydrogen propulsion nacelle prototype. In July 2022, the first distributed pod system took to the skies on a scaled-down aircraft at “Hub Drones - Systematic” airfield near Paris. The hydrogen flight received clearance from the French civil air authorities (DGAC).
H3 Dynamics’ self-contained nacelle approach addresses technical, safety and cost challenges hydrogen aircraft developers could face at some point in the future. It achieves this by placing hydrogen and smaller fuel cells across a series of collaborative propulsion nacelles under the wings. A new 2022 study forecasts the global thrust nacelle market to reach $7 Billion by 2030 highlights H3 Dynamics’ hydrogen solution as a key new opportunity in the sector.
Other, higher-visibility hydrogen aircraft proponents will fly larger size aircraft much sooner – but they will do so by converting existing aircraft using fuel cells sourced from the automotive world – and storing large amounts of gas or liquid hydrogen inside the main fuselage.
“Not only is safety our first priority, but we don’t want hydrogen competing for revenue-generating airfreight and passenger space,” said Taras Wankewycz, Founder/CEO of H3 Dynamics. Distributing small systems solves technical headaches, such as thermal management, and increases safety through multiple redundancy.
H3 Dynamics’ 25kg test aircraft is already a breakthrough - with an electric flight range of up to 900km on liquid hydrogen, or 350km with pressurized hydrogen. Its externalized nacelle design also frees up 30L of fuselage volume with no hydrogen nor any powertrain elements inside. H3 Dynamics’ hydrogen propulsion nacelles could potentially become a “snap-on” retrofit for battery-powered unmanned eVTOL or fixed wing cargo drones.
Preparing for the arrival of much longer duration unmanned hydrogen flights - H3 Dynamics started to work on airspace safety with world-leading air traffic control companies. It has been building experience with high-volume enterprise data services being deployed in smart cities such as Singapore, and gradually coupling these with drone-agnostic charging stations.
By starting at the lower-end boundary of regulatory and certification efforts, H3 Dynamics doesn’t need to wait until 2035 to begin its commercial journey. “We all need to learn today with small commercial applications and gradually increase aircraft size over time together with all stakeholders – most importantly, the regulators.”
Now H3 Dynamics is already preparing its next steps.
It is exploring liquid hydrogen integration as part of a joint-development with ISAE-SUPAERO in Toulouse launched in 2019. The objective is a historical and symbolic Atlantic crossing on hydrogen electric propulsion in the coming two years.
And with airfield experiments feeding its digital twin capability for hydrogen aircraft design, H3 Dynamics is now working on a next generation platform powered by 6 independent hydrogen-electric nacelle systems. The aircraft will feature fast-refueling and will be used as a test bed for H3 Dynamics hydrogen-electric propulsion technology moving forward.
About H3 Dynamics: www.h3dynamics.com
H3 Dynamics is on a long-term mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. While the commercial opportunities around passenger-scale hydrogen aviation continue to mature, the company is implementing an incremental product and services roadmap that solves safety, technical, regulatory challenges starting small and simple, adding scale and complexity over time. The company currently has 95 employees and serves clients globally from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is member of the Alliance for Zero Emission Aviation under the European Commission, the Lufthansa Cleantech Hub, Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121006001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom